An open-label randomized trial has been conducted to test the efficacy of IFN beta-1b, lopinavir–ritonavir and ribavirin for treating patients admitted to hospital with COVID-19 and concluded early triple antiviral therapy was effective in alleviating symptoms and shortening the duration of hospital stay in patients with mild to moderate infections (Hung, et al., 2020).